Protocol Ledger

NCT04456803 · Phase III · COMPLETED

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Interventional Phase III clinical trial protocol NCT04456803 sponsored by Sinomune Pharmaceutical Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-24 Enrollment: 239 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04456803
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)239 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04456803
Protocol FieldVerified Registry Value
NCT IdentifierNCT04456803
Consolidated Lead SponsorSinomune Pharmaceutical Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment239 participants (ACTUAL)
Registered Start Date2019-05-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI